Abstract: The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by BCL-2 and having the Formula (A):
Type:
Grant
Filed:
July 14, 2023
Date of Patent:
November 3, 2026
Assignee:
Eil Therapeutics, Inc.
Inventors:
Volodymyr Kysil, Vladislav Zenonovich Parchinsky, Alexei Pushechnikov, Alexandre Vasilievich Ivachtchenko, Ruben Abagyan, Andrew Orry, Polo Chun-Hung Lam, Nikolay Savchuk
Abstract: This application relates to novel substituted azacyclohexyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPA).
Abstract: The present invention relates to a compound of formula (I), wherein, R1, A, A5, A6, A7, A8, R12, n and Q are as defined in the detailed description and a process for preparing the compound of formula (I). The present invention also relates to a method for controlling or preventing phytopathogenic fungi.
Abstract: A sterile storage stable ready-to-inject epinephrine composition contained within a flexible container and packaged within a secondary container, the composition including an aqueous pharmaceutically acceptable carrier containing epinephrine and a metal ion chelator, the epinephrine being present in a concentration of equal to or less than 0.07 mg/mL, substantially all of the epinephrine being an R-isomer, the composition having a pH of between 3.5-4.7, and the composition having, after storage of at least one month at 25° C., total impurities of equal or less than 0.7% and equal or less than 4% S-isomer content.
Type:
Grant
Filed:
July 8, 2025
Date of Patent:
October 13, 2026
Assignee:
NEVAKAR INJECTABLES INC.
Inventors:
Prem Sagar Akasapu, Kumaresh Soppimath, Reema Ajitkumar Puri, Iouri V. Ilitchev, Milan Patel, Pooja H. Tendulkar
Abstract: A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester.
Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
Type:
Grant
Filed:
November 26, 2021
Date of Patent:
September 29, 2026
Assignee:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Claudio Fiorelli, Paolo Bruno, Matteo Biagetti, Charles Baker-Glenn, Hervè Van De Poël
Abstract: The present invention includes compositions and methods for treating or preventing certain dermal disorders including dermal atrophy, pseudoscars, actinic keratosis, seborrheic or actinic keratoses, lentigines, focal areas of dermal thickening, and coarse wrinkles. In certain embodiments, the compositions useful within the invention comprise a therapeutically effective amount of a mTORC1 inhibitor and a dermatologically acceptable carrier.
Type:
Grant
Filed:
August 11, 2021
Date of Patent:
August 25, 2026
Assignee:
Drexel University
Inventors:
Christian Sell, Timothy Nacarelli, Ashley Azar
Abstract: The present invention relates to a pharmaceutical composition for improving or treating hypoparathyroidism caused by damage to parathyroid tissue and vascular tissue around the parathyroid gland due to surgery around the neck, and a method for treating post-surgical hypoparathyroidism using the same, and the composition can promote secretion of parathyroid hormone by containing a calcium-sensing receptor antagonist as an active ingredient to help the restoration of damaged parathyroid tissue through neovascularization and angiogenesis, and furthermore, can alleviate hypocalcemia, hyperphosphatemia, and hypercalciuria by increasing the concentration of blood parathyroid hormone to a normal range level. Administration of the composition can improve the quality of life of patients with hypoparathyroidism.
Type:
Grant
Filed:
May 13, 2020
Date of Patent:
August 18, 2026
Assignee:
DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Han Seok Choi, Yun Sung Lim, Kwang Joon Kim
Abstract: Stabilized formulations of nucleic acids, including lipid nanoparticle formulations which encapsulate nucleic acids, are provided. Methods of making and of use of the formulations stabilized by chemical compounds are also provided.
Abstract: The present disclosure provides polysorbate 20 compositions with particular fatty acid ester concentrations. In some embodiments, they may be used in pharmaceutical formulations, for example, to improve stability.
Type:
Grant
Filed:
October 26, 2023
Date of Patent:
July 28, 2026
Assignee:
Genentech, Inc.
Inventors:
Sandeep Yadav, Nidhi Doshi, Tomanna Shobha, Anthony Tomlinson, Amit Srivastava
Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Type:
Grant
Filed:
December 2, 2022
Date of Patent:
June 2, 2026
Assignee:
Incyte Corporation
Inventors:
Xin Li, Michael Liang, Evan Styduhar, Robert Swyka, Oleg Vechorkin, Anlai Wang, Lin You, Peng Zhao, Ke Zhang, Minh Nguyen
Abstract: The present invention relates to an amide derivative compound, which exhibits the activity of a diacylglycerol acyltransferase (DGAT) 2 inhibitor and is represented by chemical formula (1), a pharmaceutical composition comprising same as an active ingredient, and a use thereof.
Type:
Grant
Filed:
December 22, 2020
Date of Patent:
May 26, 2026
Assignee:
LG CHEM, LTD.
Inventors:
Seung Hyun Yoon, Hyun Woo Joo, Bo Kyung Seo, Eun Jin Lee, Jin Young Jung, Su Young Yoon, Young Shin Kwak, Woo Young Cho, Min Mi Jo
Abstract: The present disclosure provides compositions and methods for treating pulmonary hypertension. The compositions and methods are based on administering a NO-releasing compound, such as nitrite, to a subject in need thereof in an amount sufficient to increase the level of circulating nitric oxide (NO), a potent vasodilator, thereby reducing the subject's blood pressure and increasing blood flow.
Abstract: The present invention provides a combination of a 5HT3-antagonist and/or a NK-1 antagonist with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, zonisamide or a pharmaceutically acceptable salt or solvate thereof, or a statin or a pharmaceutically acceptable salt or solvate thereof, for use for treating a protein misfolding neurodegenerative disease such as Alzheimer's disease, Lewy body disease, Parkinson's disease, or Huntington's disease.
Type:
Grant
Filed:
September 25, 2019
Date of Patent:
May 12, 2026
Assignee:
ALTO NEUROSCIENCE, INC.
Inventors:
Thomas N. Chase, Kathleen E. Clarence-Smith
Abstract: Disclosed herein are heterocyclic compounds that activate GLP-1R pathways. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the GLP-1R agonists are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes, obesity, and other diseases or conditions dependent on GLP-1R pathways.
Type:
Grant
Filed:
March 28, 2025
Date of Patent:
May 5, 2026
Assignee:
BIOMEA FUSION, INC.
Inventors:
Xiaodong Wang, Thorsten A. Kirschberg, Johannes H. Voigt, Thomas Butler, Ravindra B. Upasani, Yongli Su, Thu Phan, James T. Palmer, Neil Howard Squires, Yeyu Cao, Solomon B. Ungashe, Nan-Horng Lin, Mini Balakrishnan, Petr Jansa, Satish Goud Pappali
Abstract: The present invention relates to a crystal form of a compound of Formula (I), i.e. (2-((5-chloro-2-((2-methoxy-4-(9-methyl-3,9-diaza-spiro[5.5]undecan-3-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide. The present invention further relates to a pharmaceutical composition of the crystal form, and the pharmaceutical use thereof and a preparation method therefor.
Abstract: The present invention relates to process for preparation of Form I polymorph of 1-[(6-chloro-3-pyridyl) methyl]-N-nitroimidazolidin-2-ylideneamine (imidacloprid). In particular the present invention relates to process for preparation of Form I of imidacloprid containing dimer impurity?0.5%.
Type:
Grant
Filed:
January 22, 2020
Date of Patent:
March 10, 2026
Assignee:
UPL LTD
Inventors:
Prashant Vasant Kini, Vilas Manikant Mukadam
Abstract: Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
Type:
Grant
Filed:
May 9, 2024
Date of Patent:
February 24, 2026
Assignee:
Arvinas Operations, Inc.
Inventors:
Erika Marina Vieira Araujo, Michael Berlin, Hanqing Dong, Steven M. Sparks, Jing Wang, Wei Zhang
Abstract: The present invention relates to a slow release formulation. It relates also to the use of said repellent formulation, to a method of use thereof, and to a composition comprising said formulation. It further relates to PMD glucovanillin conjugate compound of formula (II), a process for preparing the compound of formula (II), and further to the use of the compound of formula (II) for the controlled release of PMD. It refers also to a process for isolating racemic cis/trans-PMD from an extract containing PMD.
Type:
Grant
Filed:
November 24, 2022
Date of Patent:
January 27, 2026
Assignee:
GLYCOSCIENCE, S.L.
Inventors:
Peter William Sutton, Lluís Bosch Hereu